Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol

被引:306
作者
Lacroix, R. [1 ,2 ]
Judicone, C. [3 ]
Poncelet, P. [3 ]
Robert, S. [1 ]
Arnaud, L. [2 ]
Sampol, J. [1 ]
Dignat-George, F. [1 ,2 ]
机构
[1] Aix Marseille Univ, UFR Pharm, INSERM, UMR1076, Marseille, France
[2] CHU Concept, AP HM, Hematol Lab, Marseille, France
[3] Biocytex, Marseille, France
关键词
microparticles; pre-analytics; standardization; CELL-DERIVED MICROPARTICLES; PLATELET MICROPARTICLES; MEMBRANE MICROPARTICLES; ENDOTHELIAL-CELLS; FLOW-CYTOMETRY; BLOOD; VARIABILITY; PLAYERS; NEEDLE;
D O I
10.1111/j.1538-7836.2011.04610.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
. Background: Microparticles (MP) are small vesicles of 0.11 mu m, released in response to activation or apoptosis. Over the past decade, they received an increasing interest both as biomarkers and biovectors in coagulation, inflammation and cancer. Clinical studies were conducted to assess their contribution to the identification of patients at cardiovascular risk. However, among the limitation of such studies, pre-analytical steps remains an important source of variability and artifacts in MP analysis.Objectives: Because data from the literature are insufficient to establish recommendations, the objective of the present study was to assess the impact of various pre-analytical parameters on MP measurement. These parameters included the type of collection tube, phlebotomy conditions, transportation practices, centrifugation steps and freezing. Methods: MP were assessed by three methods: flow cytometry using a standardized approach, a thrombin generation test (Calibrated Automated Thrombogram (R)) and a procoagulant phospholipid-dependent clotting time assay (STA (R)-Procoag-PPL). Results: The main results show that the three major pre-analytical parameters which impact on MP-related data are the delay before the first centrifugation, agitation of the tubes during transportation and the centrifugation protocol. Conclusions: Based on both this work and literature data, we propose a new protocol that needs to be validated on a larger scale before being applied for multicenter studies.
引用
收藏
页码:437 / 446
页数:10
相关论文
共 43 条
[1]  
Ahmad S, 2005, J THROMB HAEMOST, V3, P372
[2]   Microvesicles Messengers and mediators of tumor progression [J].
Al-Nedawi, Khalid ;
Meehan, Brian ;
Rak, Janusz .
CELL CYCLE, 2009, 8 (13) :2014-2018
[3]   The role of microparticles in inflammation and thrombosis [J].
Ardoin, S. P. ;
Shanahan, J. C. ;
Pisetsky, D. S. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2007, 66 (2-3) :159-165
[4]   Measurement of circulating cell-derived microparticles by flow cytometry: Sources of variability within the assay [J].
Ayers, Lisa ;
Kohler, Malcolm ;
Harrison, Paul ;
Sargent, Ian ;
Dragovic, Rebecca ;
Schaap, Marianne ;
Nieuwland, Rienk ;
Brooks, Susan A. ;
Ferry, Berne .
THROMBOSIS RESEARCH, 2011, 127 (04) :370-377
[5]   Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner [J].
Biró, É ;
Sturk-Maquelin, KN ;
Vogel, GMT ;
Meuleman, DG ;
Smit, MJ ;
Hack, CE ;
Sturk, A ;
Nieuwland, R .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (12) :2561-2568
[6]  
Biró É, 2004, J THROMB HAEMOST, V2, P382
[7]   Circulating microparticles - A potential prognostic marker for atherosclerotic vascular disease [J].
Boulanger, Chantal M. ;
Amabile, Nicolas ;
Tedgui, Alain .
HYPERTENSION, 2006, 48 (02) :180-186
[8]   Microparticles and thrombotic disease [J].
Davizon, Pavel ;
Lopez, Jose A. .
CURRENT OPINION IN HEMATOLOGY, 2009, 16 (05) :334-341
[9]   Cellular microparticles: new players in the field of vascular disease? [J].
Diamant, M ;
Tushuizen, ME ;
Sturk, A ;
Nieuwland, R .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (06) :392-401
[10]  
Dignat-George F., 2004, J THROMB HAEMOST, V2, P1844, DOI DOI 10.1111/J.1538-7836.2004.00938.X